ACE INHIBITOR MARKET SWITCH TO GENERICS MAY BE HELD BACK BY MERCK-MEDCO TACTICS, LAW FIRM TELLS FTC; FDA MAINTAINS INTEREST IN PBM MARKETING TECHNIQUES
The uptake of generics within the ACE inhibitor category when captopril comes off patent may be slowed by preferred product choices currently being made by Medco, the Washington, D.C. law firm of Fox, Bennett & Turner maintains in recent comments to the Federal Trade Commission.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth